Why we're lowering our Bristol Myers price target despite an earnings beat, guidance raise
Shares of Bristol Myers Squibb fell modestly after the drugmaker's better-than-expected first-quarter results.
Tfoso
0
6
The logo of the pharmaceutical company Bristol-Myers Squibb, (BMS) is seen on the facade of the company's Munich headquarters on August 29, 2024 in Munich (Bavaria).
Matthias Balk | Picture Alliance | Getty Images
Bristol Myers Squibb's earnings beat and rosy outlook Thursday did not resolve lingering issues for the stock. But it was enough, for now.
